Compare Novo Nordisk A/S (NVO) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Synchrony Financial — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Synchrony Financial trades at $71.7 (market cap $24.69B). The key difference: Novo Nordisk A/S is far larger — about 8.9× Synchrony Financial's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | SYF | |
|---|---|---|
Market Cap | $220.53B | $24.69B |
Sector | Health | Financials |
52-Week High | $71.70 | $88.47 |
52-Week Low | $35.29 | $63.78 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | 1.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
